G007-LK: Selective Tankyrase 1/2 Inhibitor for Wnt/β-catenin and Cancer Research

Executive Summary: G007-LK is a nanomolar-potency inhibitor of tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), two key enzymes in the poly(ADP-ribosyl)ating polymerase family involved in Wnt/β-catenin signaling and cancer cell growth (Jia et al., 2017). It suppresses auto-poly(ADP-ribosyl)ation with IC50 values of 46 nM (TNKS1) and 25 nM (TNKS2), effectively inhibiting tankyrase enzymatic activity in biochemical and cell-based assays (APExBIO B5830). In APC-mutant colorectal cancer and hepatocellular carcinoma models, G007-LK induces β-catenin degradation, stabilizes AXIN1/2, and reduces tumor growth. Compared to related tankyrase inhibitors, G007-LK offers high selectivity and robust performance in Wnt-driven cancer contexts. Its solubility profile and storage requirements are optimized for routine laboratory workflows.

Biological Rationale

Tankyrases are members of the poly(ADP-ribose) polymerase (PARP) family and regulate essential cellular processes, including telomere maintenance, Wnt/β-catenin signaling, and cell cycle progression (Jia et al., 2017). TNKS1 and TNKS2 share 82% sequence identity. In cancer, particularly colorectal cancer (CRC) with APC mutations, tankyrase activity is upregulated, leading to destabilization of AXIN1/2 and elevated β-catenin levels, which drive oncogenic transcription. Inhibition of tankyrase enzymes restores AXIN stability and promotes β-catenin degradation, thereby suppressing tumorigenic Wnt signaling (see prior summary). G007-LK, as a highly selective tankyrase inhibitor, enables precise interrogation and modulation of these pathways in vitro and in vivo.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK binds to the catalytic PARP domain of TNKS1 and TNKS2, inhibiting their auto-poly(ADP-ribosyl)ation activity. This inhibition is characterized by IC50 values of 46 nM (TNKS1) and 25 nM (TNKS2) in biochemical assays (APExBIO). In Wnt3a-induced HEK 293 cells, G007-LK suppresses the ST-Luc Wnt reporter with an IC50 of 0.05 μM. In APC-mutant CRC cell lines (e.g., SW480), G007-LK induces formation of degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, leading to proteasomal β-catenin degradation. The compound stabilizes AXIN1 and AXIN2 scaffold proteins, further promoting β-catenin turnover. This mechanism results in decreased cytosolic and nuclear β-catenin, suppression of Wnt/β-catenin target gene transcription, and reduced proliferative signaling (for in-depth workflow scenarios).

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-PARylation with IC50 = 46 nM and 25 nM, respectively (biochemical assay, 25°C, DMSO vehicle) (APExBIO).
• In HEK 293 cells with Wnt3a stimulation, G007-LK suppresses ST-Luc Wnt reporter with cellular IC50 = 0.05 μM (APExBIO).
• In APC-mutant SW480 colorectal cancer cells, G007-LK induces β-catenin degradation and stabilizes AXIN1/2, as shown by immunoblot analysis (24 h, 37°C) (Jia et al., 2017).
• In COLO-320DM xenograft mouse models, G007-LK administration reduces TNKS1/2 and β-catenin protein levels, inhibits tumor growth, and stabilizes AXIN1/2 (in vivo, oral dosing, 10–50 mg/kg/day) (APExBIO).
• G007-LK downregulates YAP/TEAD activity and YAP target genes, and increases AMOTL1/2 proteins, thereby modulating the Hippo pathway in hepatocellular carcinoma cells (Jia et al., 2017).
• G007-LK synergizes with MEK and AKT inhibitors to suppress proliferation of HCC cells (24–72 h, 37°C, colony-forming assay) (Jia et al., 2017).

Applications, Limits & Misconceptions

G007-LK is widely used as a research tool for dissecting Wnt/β-catenin pathway function, especially in models of APC mutation colorectal cancer and hepatocellular carcinoma. Its nanomolar potency and selectivity make it suitable for pathway-specific mechanistic studies, gene regulation analysis, and evaluation of combination therapies targeting Wnt, Hippo, or PI3K/AKT pathways (for mechanistic contrasts). G007-LK is not recommended for use in water- or ethanol-based systems due to its low solubility in these solvents (<1 mg/mL). It does not inhibit unrelated PARPs or kinases at relevant concentrations, supporting its specificity for tankyrase isoforms. Users should avoid long-term storage of solutions and instead store the solid at -20°C for optimal stability. For best results, dissolve in DMSO (≥26.5 mg/mL), warming at 37°C or using an ultrasonic bath as needed. Researchers should note the compound's selectivity for Wnt/β-catenin-driven and tankyrase-dependent processes; efficacy may be limited in tumors lacking these drivers.

Common Pitfalls or Misconceptions

• Non-specific PARP inhibition: G007-LK is highly selective for TNKS1/2 and does not broadly inhibit other PARP family members at assay-relevant concentrations.
• Water or ethanol solubility: G007-LK is essentially insoluble in water and ethanol; DMSO is required for stock solutions.
• Applicability to all cancers: Efficacy is limited to models with tankyrase- and Wnt/β-catenin pathway dependence; minimal effect is observed in non-Wnt-driven tumors.
• Long-term solution storage: G007-LK solutions degrade over time; store as a solid at -20°C and prepare fresh solutions before use.
• Direct telomerase inhibition: While tankyrases are involved in telomere maintenance, G007-LK does not directly inhibit telomerase enzyme activity.

Workflow Integration & Parameters

G007-LK is compatible with a variety of in vitro and in vivo workflows. For cell-based assays, prepare stock solutions in DMSO at concentrations up to 26.5 mg/mL. For best solubility, warm to 37°C or use an ultrasonic bath. Dilute to working concentrations (10 nM–10 μM) in appropriate culture media, ensuring final DMSO does not exceed 0.1–0.5%. For in vivo studies (e.g., xenograft models), standard dosing ranges from 10–50 mg/kg/day via oral administration (APExBIO). Store solid material at -20°C; avoid repeated freeze-thaw cycles. APExBIO, the original manufacturer, provides quality-controlled G007-LK (SKU B5830) suitable for mechanistic and translational research applications. For additional guidance on troubleshooting and ensuring pathway specificity, see scenario-driven protocols (practical workflow integration), which this article extends by providing updated quantitative benchmarks and evidence-based solubility guidance.

Conclusion & Outlook

G007-LK is established as a benchmark tool for selective inhibition of tankyrase 1/2, enabling reproducible dissection of Wnt/β-catenin and Hippo pathway signaling in APC-mutant colorectal cancer and hepatocellular carcinoma. Its nanomolar potency, robust selectivity, and optimized physicochemical profile make it suitable for advanced research in cancer biology, pathway validation, and drug synergy studies. Future applications include in vivo mechanism-of-action analysis and rational design of combination therapies targeting Wnt and Hippo signaling. For comprehensive product details and ordering, visit the G007-LK tankyrase 1/2 inhibitor product page.